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Guanylin, a peptide implicated in regulation of intestinal fluid secretion, is expressed in the mucosa, but 
the exact cellular origin remains controversial. In a new transgenic mouse model fluorescent reporter 
protein expression driven by the proguanylin promoter was observed throughout the small intestine 
and colon in goblet and Paneth(-like) cells and, except in duodenum, in mature enterocytes. In Ussing 
chamber experiments employing both human and mouse intestinal tissue, proguanylin was released 
predominantly in the luminal direction. Measurements of proguanylin expression and secretion in cell 
lines and organoids indicated that secretion is largely constitutive and requires eR to Golgi transport but 
was not acutely regulated by salt or other stimuli. Using a newly-developed proguanylin assay, we found 
plasma levels to be raised in humans after total gastrectomy or intestinal transplantation, but largely 
unresponsive to nutrient ingestion. By LC-MS/MS we identified processed forms in tissue and luminal 
extracts, but in plasma we only detected full-length proguanylin. Our transgenic approach provides 
information about the cellular origins of proguanylin, complementing previous immunohistochemical 
and in-situ hybridisation results. The identification of processed forms of proguanylin in the intestinal 
lumen but not in plasma supports the notion that the primary site of action is the gut itself.
Guanylin is a small peptide produced in the intestinal mucosa from the Guca2a gene which has established roles 
in intestinal fluid homeostasis and maintenance of gut physiology. Together with the related peptide uroguanylin 
(encoded by the Guca2b gene), and heat-stable enterotoxin STa, guanylin activates the Guanylate Cyclase C recep-
tor (GC-C)1, which is encoded by the Gucy2c-gene and expressed along the gastrointestinal (GI) tract. Unusually 
for a gut peptide/receptor combination, however, the peptide appears to access its receptor from the luminal 
direction2–4. GC-C activation catalyses the generation of cGMP, stimulating transepithelial chloride flux, inhibi-
tion of sodium proton exchangers5, and increase in water movement into the intestinal lumen6. Overstimulation 
or gain of function mutations in GC-C lead to altered GI transit diarrhoea, and loss of function mutations have 
been associated with meconium ileus in infants7–9.
The reported active 15 amino acid bioactive peptide guanylin derives from the C-terminus of a longer 
pre-proguanylin peptide, which comprises a signal sequence (residues 1–21) and proguanylin (residues 22–116 
in the mouse sequence, 22–115 in the human). A number of reports have suggested that proguanylin is the pre-
dominant secreted form of the peptide, but the enzymatic pathway underlying proguanylin processing to generate 
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bioactive guanylin remains unclear10. Previous studies aimed to address the potential cellular origin of guanylin. 
Early reports suggested, based on the hormonal function proposed for guanylin peptides, that enteroendocrine 
cells were the likely source of these peptides, including enterochromaffin cells11,12 and somatostatin secreting 
D-cells13. However, other cell types were also reported as sources of guanylin, including goblet cells14–16, Paneth 
cells10,17, colonic Paneth-like cells16, tuft cells and enterocytes16,18, but with some discrepancies between tech-
niques and studies. Stimuli underlying proguanylin secretion remain poorly characterised, with the strongest 
body of evidence supporting a link to salt consumption19,20, corresponding with an observed increase in Guca2a 
expression in the intestines of rats fed a high salt diet21.
The GC-C signalling axis has been reported to play a role in crypt-villus epithelial proliferation and to act as a 
tumour suppressor gene. Reduced GC-C receptor signalling was linked to hyperplasia of crypts and villi along the 
gastrointestinal tract and was associated with increased susceptibility to tumorigenesis22. In a cohort of patients 
with stage I-III colorectal cancer, guanylin mRNA and peptides were lost and/or significantly lower in cancerous 
tissues compared to healthy adjacent tissues in >85% of cases23, and targeting the GC-C pathway at the early 
stages of colorectal cancer has been proposed as a candidate therapeutic strategy24–27.
Circulating proguanylin levels were lower in people with obesity and raised following Roux-en-Y gastric 
bypass surgery28, suggesting potential links to metabolism or food intake. Corresponding with these findings, 
mice fed a high fat diet had lower expression and peptide levels of guanylin and forced re-expression of guanylin 
reduced the rate of obesity associated colorectal cancer29. Gucy2c-deficient mice are hyperphagic and heavier 
compared with wild-type mice30. In wild-type mice, food intake was reduced following intravenous administra-
tion of prouroguanylin, but not proguanylin, and increased following treatment with a prouroguanylin antiserum 
and it was speculated local processing in the hypothalamus releases active uroguanylin30,31, suggesting a central 
role for GC-C signalling. However, another group found that neither systemic nor central administration of 
proguanylin-derived peptides modulated food ingestion or glucose homeostasis in mice28, despite targeting the 
same GC-C receptor. GC-C activation has, however, been shown to stimulate secretion of the anorectic peptide 
glucagon-like peptide-1 (GLP-1) from enteroendocrine cells in the GI tract32.
Despite the multiple proposed physiological roles of guanylin peptides and increased interest in their use for 
treating irritable bowel syndrome or colorectal cancer33, the cellular origins of guanylin and the mechanisms 
underlying its secretion are poorly understood. To address these questions, we generated a transgenic mouse 
model in which the Guca2a promoter drives the expression of the yellow fluorescent protein Venus. This model 
was utilised alongside the use of mass spectrometry and a newly-established monoclonal antibody-based immu-
noassay to measure proguanylin and proguanylin-derived peptides in human plasma, tissues and cell superna-
tants isolated from preclinical experimental systems.
Results
proguanylin levels in human plasma. By LC-MS/MS, we detected high levels of proguanylin (22–115) 
in human plasma, but were not able to detect shorter proguanylin-derived peptides containing the C-terminal 
active sequence (Fig. 1a). Therefore, this suggests that proguanylin is mostly circulating as the intact profom 
which we could detect using a newly developed proguanylin immunoassay. Fasting plasma proguanylin levels in 
healthy humans were 15.2 ± 2.7 ng/mL (mean ± sd), and followed a normal distribution (Fig. 1b). Plasma levels 
fell slightly after a 75 g or 50 g oral glucose tolerance test but there was no significant effect of a mixed liquid meal 
(Fig. 1c,d). Lean patients who had undergone total gastrectomy with Roux-en-Y reconstruction for gastric cancer 
had elevated fasting proguanylin concentrations (26.5 ± 6.9 ng/mL)), but no significant change after oral glucose 
ingestion (Fig. 1d). Although a number of the gastrectomy patients carried risk alleles in CDH1, neither pre- nor 
post-operative proguanylin levels appeared influenced by the CDH1 genotype. Fasting proguanylin concentra-
tions were elevated in a proportion of subjects who had undergone small bowel transplantation (Fig. 1e). One 
transplant subject had blood samples collected after removal of the small and large intestine and again after bowel 
transplantation, revealing very low proguanylin after intestinal removal (~0.2 ng/ml, close to the detection limit of 
the assay) but a normal level (19.4 ng/ml) after transplantation. Collectively, these results provide strong support 
for the idea that the gut is the predominant source of proguanylin in human blood, which circulates at relatively 
high levels compared to other intestinally derived hormones, such as GLP-1.
Identification of proguanylin-derived peptides by LC-MS/MS. Analysis of tissue homogenates from 
sequential sections along the mouse small intestine, colon and rectum34 by LC-MS/MS did not detect proguanylin 
itself, likely because other peptides eluted with similar retention times, but identified several proguanylin-derived 
peptides (Fig. 2a). Whilst these were barely detectable in homogenates from the proximal duodenum, lev-
els increased along the GI tract before falling again in the rectum. Interestingly, the canonical sequence for 
the reported active 15 amino acid peptide (position m-102–116) was present at extremely low levels in tissue 
homogenates and detectable only in jejunum and colon, whereas a form containing one additional amino acid at 
the N-terminus was readily detected in all samples.
Similar analysis of the apical and basolateral solutions from murine jejunum and colon mounted in Ussing 
chambers (after 120 min each from one colon and one jejunum) identified full length proguanylin (22–116) in 
both solutions, although at much higher concentrations in the apical compartment (Fig. 2b–d). In the apical 
compartments of both tissues we also identified several proguanylin derived peptides such as 60–88, 101–116, 
103–116 and 104–116 (Fig. 2b,e). The same peptides were detected in the basolateral compartments, but at much 
lower concentrations, mirroring the lower levels of proguanylin. Immunoassay measurements of proguanylin 
from human colonic tissues mounted in Ussing chambers also revealed much higher levels released into apical 
than basolateral compartments (Fig. 2f). Forskolin + IBMX had only a minor effect on proguanylin secretion, 
although this was a strong stimulus of GLP-1 release into the basolateral compartment, measured in parallel.
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Mapping guanylin-expressing cells along the murine gut axis. We were unable to detect specific 
immunohistochemical staining with the monoclonal antibodies isolated during the development of the new 
immunoassay in human intestinal tissue slices or primary mixed epithelial cultures (data not shown). Instead, 
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Figure 1. Proguanylin detection in plasma. (a) LC-MS/MS evidence of full length proguanylin in human 
plasma. Right panel shows the total ion chromatogram for an m/z range corresponding to the proguanylin in a 
charge state of 8 (±0.01 around each isotopic variants), asterisk marks the peak corresponding to proguanlyin, 
left panel is the m/z distribution at retention time corresponding to the peak marked by an asterisk. (b) Data 
distribution and normality for proguanylin concentration in plasma of fasted healthy volunteers (n = 51). 
Skewness = 0.37; kurtosis = −0.08; P = 0.69 when evaluated for Shapiro-Wilk test. (c) Effect of liquid meal 
(n = 28) or 75 g OGTT (n = 12) on plasma proguanylin levels in healthy volunteers after 60 minutes. (d) Effect of 
50 g glucose ingestion on plasma proguanylin levels of healthy controls and participants with total gastrectomy 
after 60 minutes (n = 17, controls: n = 11). Patients with a mutation in the CDH1 are indicated in orange. (e) 
Serum levels of proguanylin in fasting healthy volunteers and patients following intestinal transplantation. 
*p < 0.05 and ***p < 0.001 using a paired t-test when comparing intra individual values across two time points 
or unpaired t-tests when comparing two groups of individuals.
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Figure 2. Proguanylin production and secretion in the gut. (a) Measurement of GUCA2A peptides along the 
mouse intestine from duodenum to rectum (1 to 7 are small intestine regions every 5 cm from duodenum to 
ileum, and 8 to 10 are proximal colon, distal colon and rectum respectively) analysed by LC-MS/MS. Data are 
mean ± SEM, n = 4. (b) Apical (dark colours) and basolateral (light colours) secretion of guanylin peptides 
from mouse colonic (red) and jejunum (blue) tissues). (c,d) Evidence of full length proguanylin (marked by 
asterisk) in mouse jejunum apical compartment (c) and absence in the basolateral compartment (d) showing 
chromatogram for the m/z range corresponding to the [M + 8 H]8+ charge state of proguanylin (left panel) and 
the m/z distribution at the expected retention time. (e) PEAKS peptidomics search results showing peptides 
(of less than 65 amino acids) matching the proguanylin sequence in the apical side of the Ussing chamber 
experiment using murine colonic tissue. (f) Apical (blue) and basolateral (green) secretion of proguanylin and 
basolateral secretion of GLP1 from human colonic tissues using Ussing chambers from 6 tissue preparations 
from 4 different donors. Data are represented as mean ± SD * and #p < 0.05 using a paired t-test adjusting for 
multiple testing, comparing apical vs basolateral secretion and unstimulated vs F/I stimulated.
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a transgenic mouse model was designed to identify which cell types produce proguanylin, by expression of the 
fluorescent protein Venus under the control of the guanylin promoter. The line was derived from one founder in 
which a BAC construct containing the Venus sequence in place of the coding sequence of Guca2a was incorpo-
rated into the mouse genome (Fig. 3a). Offspring showed fluorescence in the small and large intestine, enabling 
the use of fluorescence-assisted cell sorting (FACS) to separate fluorescent (positive) from non-fluorescent (neg-
ative) cells separately from the duodenum, jejunum, ileum and colon. RT-qPCR analysis of sorted positive and 
negative cell populations showed enrichment of Guca2a and Venus expression in the fluorescent populations, 
thus validating the model (Fig. 3b,c). Interestingly, the fluorescent cell populations were also enriched for the 
expression of uroguanylin, Guca2b (Fig. 3d).
The proportion of Venus fluorescent cells was highly variable between different intestinal tissues. Using flow 
cytometry to count the number of cells exhibiting fluorescence above a fixed threshold, we estimated that the 
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Figure 3. Generation and characterisation of the guanylin-Venus mouse. (a) Schematic depicting the insert of 
BAC RP23-104G3 and replacement of the Guca2a coding region from exons 1–3 with the yellow fluorescent 
protein Venus. Lengths (in kb) of the murine genomic sequence 3′ and 5′ of the Guca2a coding region in the 
BAC are indicated. (b–d) RT-qPCR analysis of FACS sorted positive (green) and negative (blue) populations 
for each tissue for Guca2a (b), Venus (c) and Guca2b (d) n = 3 each; negative and positive populations were 
compared using paired t-test *P < 0.05 **P < 0.01. (e–h) duodenum (e), jejunum (f), ileum (g) and colon (h) of 
Guca2a-Venus mice immunostained for GFP (green) and DNA (Hoechst; purple).
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Venus-positive cell frequency was ~3% of the epithelial cell population in the duodenum, ~50% in the jeju-
num, 30% in the ileum and 20% in the colon. Immunostaining of tissue sections confirmed this disparity in 
guanylin-expressing cell distribution along the intestinal axis (Fig. 3e–h). Duodenum contained only scarce 
Venus positive cells that were scattered along the crypt-villus axis (Fig. 3e). In jejunum and ileum, Venus positive 
cells appeared to separate into two distinct populations, one located at the tops of the villi and another in the 
crypts. In colon, the fluorescent marker was largely restricted to the surface epithelium at the top of the crypts 
(Fig. 2h). These staining patterns suggest that Guca2a is expressed in mature enterocytes in the jejunum, ileum 
and colon but not duodenum, as well as in some other epithelial cell types.
Identification of guanylin-expressing cells by transcriptomic profiling. To determine the identity 
of the fluorescent cells in the small and large intestine of Guanylin-Venus mice, we performed RNA sequencing 
analysis of FACS-sorted Venus-positive and -negative cell populations from four different regions of the GI tract 
of three mice each. Confirming the RT-qPCR data, both Guca2a and Guca2b were enriched in fluorescent cell 
populations from all four intestinal regions, and surprisingly, we also detected higher expression of the receptor 
GC-C (Gucy2c) in fluorescent cells from the jejunum, ileum and colon (Fig. 4d), although not duodenum. By 
principal component analysis (PCA) of the RNAseq results, the samples were found to cluster both by the tissue 
of origin and by whether they were fluorescent or non-fluorescent, indicating that Guca2a expressing cells are 
transcriptomically different from negative cells, and that they vary along the GI tract (Fig. 4a). Analysis of the top 
500 most differentially expressed genes across all groups revealed clear separations between Guca2a positive and 
negative cells, and between Guca2a-expressing cells in the duodenum compared with their counterparts in the 
jejunum and ileum (Fig. 4b). Analysis of the numbers of Guca2a-cell enriched genes in different intestinal regions 
also revealed strong similarity between Guca2a-positive cells from the ileum and jejunum compared with those 
from the duodenum (Fig. 4c). 515 genes were enriched in Guca2a-positive cells compared to negative cells from 
the same region, in all four tissues, suggesting at least a degree of overlap between the Guca2a cell populations 
from different regions of the GI tract.
To identify the cell types expressing Guca2a, we examined the expression of known marker genes for differ-
ent epithelial cell populations: goblet cells, enterocytes, Paneth cells, tuft cells, enteroendocrine cells and pro-
liferative cells (Fig. 4d and Supplementary Fig. 1). Goblet cell markers (Muc2, Tff3, Spink4) were enriched in 
positive cells across all four tissues. Enterocyte cell markers (Adh6a, Khk, Alpi, Slc16a3, Batf2) were enriched in 
guanylin-expressing cells, particularly in the jejunum and ileum, and colonocyte cell markers (Car2, Slc2a1) were 
also enriched in guanylin-expressing cells. Paneth cell markers (Lyz1 and Defa22) were enriched in positive cells 
from the small intestine but not colon, consistent with the fact that Paneth cells are not present in the colon, but 
Paneth-like cells markers (Kit, Egf) were enriched in positive cells of the colon35. Markers of Tuft cells (Dclk1, 
Lrmp, Trpm5), enteroendocrine cells (including Gcg, Gip, Pyy, Cck, Chga, Tph1) and proliferative cells (Lgr5, 
Mki67, Sox4, Stmn1, Foxm1) were relatively depleted in Guca2a-positive compared with negative cells.
Overall, this transcriptomic analysis suggests that Guca2a is expressed by several different cell populations in 
the intestinal epithelium: goblet and Paneth/Paneth-like cells in all 4 intestinal tissues, and enterocytes/colono-
cytes in tissues distal to the duodenum. Notably, Guca2a labelled cells did not exhibit expression patterns typical 
of enterocytes in the duodenum, or of enteroendocrine cells, tuft cells or proliferative cells.
Identification of guanylin-expressing cells by immunostaining. We further examined the cellular 
identity of Guca2a expressing cells by double immunostaining of tissue slices from Guca2a-Venus mice and 
by RT-qPCR of FACS-purified fluorescent cells. To address the overlap with Paneth cells, we examined expres-
sion of Lyz1, and immunostaining for lysozyme (Fig. 5). Confirming the RNAseq data, Lyz1 was enriched in 
Guca2a-fluorescent cells from different regions of the small intestine (Fig. 5a). Dual staining for lysozyme and 
Venus (using an anti-GFP antibody) showed double labelled cells at the crypt bases in the duodenum, jejunum 
and ileum (Fig. 5d–f), with the majority of lysozyme positive cells being GFP positive: 67% in the duodenum, 
91% in the jejunum and 86% in the ileum (Fig. 5b). Paneth cells represented ~50% of all Venus positive cells in 
the duodenum, but less than 15% in the jejunum and ileum, reflecting the higher overall frequencies of Guca2a 
positive cells in the jejunum and ileum (Fig. 5c).
To validate and quantify the localisation of Guca2a in goblet cells, we measured expression of the mark-
ers Muc2 by qPCR, and performed double staining for Muc2 and GFP in Guca2a-Venus tissues. Expression of 
Muc2 was enriched in Venus-positive compared with negative cells (Fig. 6a), with the most marked differential 
expression evident in the duodenum. Many cells exhibited double-positive staining for Muc2 and GFP in all four 
tissues (Fig. 6c–g), with ~50% of all goblet cells staining positive for GFP in the duodenum, jejunum and ileum 
compared with ~20% in the colon (Fig. 6b). In the duodenum, 53% of all GFP positive cells exhibited co-staining 
for Muc2, whereas Muc2-positive goblet cells represented only 9%, 16% and 19% of the total GFP-positive cell 
populations in jejunum, ileum and colon, respectively, again reflecting the higher overall frequencies of fluores-
cent cells in these tissues (Fig. 6c).
Altogether, these results show that the Guca2a positive cell population in the duodenum is largely made up of 
Paneth and goblet cells, each representing about half of all Guca2a cells in this region. In the jejunum and ileum, 
Paneth and goblet cells together only explain a third of the Guca2a positive population, the remainder being 
mature enterocytes, as further supported by the expression of the different intestinal cell-type markers by qPCR 
(Fig. 7). In the colon, only ~20% of Guca2a positive cells stained positive for Muc2, and the remainder appeared 
to be dominated by mature colonocytes.
Regulation of guanylin secretion. We next investigated whether proguanylin release could be modu-
lated by a panel of candidate stimuli known to stimulate different epithelial cell types. In particular, we tested 
agents that could potentially target a variety of cell types, including PMA to activate PKC and forskolin/IBMX to 
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Figure 4. Transcriptome analysis of Guca2a-expressing cells. (a) Principal-Component analysis of the top 
500 most variable genes between positive and negative cells from the four regions of the GI tract. Non-coding 
and mitochondrial genes were excluded. In purple are the Venus-positive cell subpopulations and in grey are 
the negative population. Tissue of origin is represented by shape (circle: duodenum; triangle: jejunum; square: 
ileum; cross: colon). (b) Heatmap showing the top 500 most differentially expressed genes between positive and 
negative cells across all 4 regions. Values are log10 normalised read counts. Genes and samples are grouped via 
hierarchical clustering based on Euclidean distance and complete linkage. Colon = red; duodenum = yellow; 
jejunum = light blue; ileum = dark blue. Purple = positive cells; grey = negative cells (c) Venn diagram 
summarising the overlap of positively-enriched genes in the guanylin-positive cell subpopulation for each 
region. Positively enriched genes were selected with p-adjusted < 0.05. (d) Heatmap of selected cell markers 
(rows) between positive and negative cells (columns sorted by cell type and tissue of origin). Values are log fold 
change compared to mean expression across all samples. Colour coding as for (b).
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increase cAMP concentrations; stimuli known to enhance secretion from enteroendocrine cells via cell surface 
receptors, including bile acids, peptones and bombesin; and stimuli previously reported to modulate guanylin 
release, including elevated salt concentrations and carbachol. Secretion was first measured from primary human 
colonic crypt cultures containing a variety of cell types, using LC-MS/MS to provide parallel quantification of a 
readily detectable proguanylin fragment 22–49 and GLP-1. After 1 h of incubation, proguanylin secretion was 
slightly enhanced by the PKC activator PMA, but was not altered by bombesin, forskolin/IBMX or an agonist of 
the Gs-protein coupled bile acid receptor GPBAR1, which robustly elevated GLP-1 (Fig. 8a,b).
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Figure 5. Guanylin expression in Paneth cells. (a) Venus-positive (green) and negative (blue) subpopulations 
of isolated intestinal cells from the Guca2a-Venus mice were analysed by RT-qPCR for Lyz1 expression. n = 2–3 
each; positive and negative populations were compared using a paired t-test *P < 0.05. (b) Proportion of 
Lyz1 only positive cells (blue) and Venus and Lyz1 double positive (green) compared to total number of Lyz1 
positive cells. (c) Proportion of Venus only positive cells (yellow) and double positive to Venus and Lyz1 (green) 
compared to total number of Venus cells. (d–f) Guca2a-Venus mice sections immunostained for Venus (GFP, 
green), lysozyme (red) and DNA (Hoechst; blue) from duodenum (d), jejunum (e) and ileum (f).
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We next used differentiated human duodenal and colonic organoids as a model of mixed epithelial cell types, 
to measure proguanylin secretion by immunoassay over 24 h in response to a panel of stimuli including sodium 
chloride, nutrients, bile acids and neurotransmitters. As expected, undifferentiated organoids had very low lev-
els of GUCA2A expression and did not secrete detectable concentrations of proguanylin, whereas GUCA2A 
expression and proguanylin secretion increased following organoid differentiation (Fig. 8e,f and Supplementary 
Fig. 2). Differentiated organoids secreted proguanylin into the medium, and in the duodenum (but not colon) this 
was marginally stimulated by 50 mM NaCl but not 100 mM mannitol (Fig. 8e,f). No other condition modulated 
proguanylin secretion in either duodenal and colonic organoids, except for an inhibition seen with PMA, con-
trasting with the slight increase observed in primary cultures after more acute (1 h) stimulation.
We then assessed candidate mechanisms regulating proguanylin secretion using a human enterocyte cell line 
model, TC7, a subclone of the Caco-2 cell line. This more homogenous culture system also allowed us to monitor 
changes in the expression of proguanylin, either after acute (4 h) or more prolonged (24 h) stimulation. Addition 
of 10 or 50 mM NaCl, or 100 mM mannitol as an osmolarity control, resulted in a reduction in proguanylin 
secretion into the media after 4 hours, with the higher NaCl and mannitol treated cells also exhibiting a corre-
spondingly lower expression of GUCA2A relative to the housekeeper gene ACTB (Fig. 8g,h). After 24 h incuba-
tion, however, proguanylin levels in salt and mannitol-treated wells were similar to those in control wells, and 
GUCA2A expression was elevated (Fig. 8i,j). We also measured proguanylin release and biosynthesis in TC7 cells 
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Figure 6. Guanylin expression in goblet cells. (a) Venus positive (green) and negative (blue) subpopulations 
were analysed by RT-qPCR for Muc2 expression. n = 2–3 populations; positive and negative populations 
were compared using a paired t-test *p < 0.05 **p < 0.01. (b) Proportion of Muc2 only positive cells (red) 
and Venus and Muc2 double positive (orange) cells in comparison to the total number of Muc2 positive cells. 
(c) Proportion of Venus only positive cells (yellow) and Venus and Muc2 double positive (orange) cells in 
comparison to the total number of Venus positive cells. (d–g) Guca2a-Venus mice sections stained for Venus 
(GFP, green), muc2 (red) and DNA (Hoechst; blue) of duodenum (d), jejunum (e), ileum (f) and colon (g).
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in response to known enteroendocrine stimuli: bombesin, carbachol, peptones, taurodeoxycholic acid, PMA and 
forskolin/IBMX. After 4 h incubation, the only stimulus that significantly increased the release of proguanylin 
was 10 μM forskolin/IBMX, corresponding with a parallel increase in GUCA2A expression (Fig. 8g,h). After 24 h, 
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Figure 7. Other cell type markers. Gene expression levels of cell markers measured by RT-qPCR on cell-
sorted Venus-positive and negative control subpopulations of Guca2a-Venus mice (n = 2–3). Markers for 
enteroendocrine cells: Gcg (a), Gip (b), Pyy(c), M cells: Ccl9 (d), Marcksl1 (e), enterocytes cells: Vil1 (f), 
tuft cells: Dclk1 (g), Trpm5 (h), Sox9 (i) and stem cells: Lgr5 (j) were checked for both negative (blue) and 
positive (green) subpopulation. Data are individual gene expression normalised to β-Actin and mean value is 
represented. Positive and negative populations were compared using a paired t-test. *p < 0.05.
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Figure 8. Proguanylin secretion in vitro. (a,b) Effect of different stimuli on proguanylin(22–49) (a) and GLP-1 
(b) secretion from primary human colonic cultures, measured by LC-MS/MS after 1 h incubation in the 
absence (basal) or presence of bombesin (100 nM), forskolin/IBMX (10 μM each), PMA (1 μM) or GPBAR-A 
(3 μM). (c,d) Quantities of proguanylin in TC7 cell supernatants (c) and lysates (d) at different time points 
in standard media (blue) with forskolin/IBMX (10 μM each, red) or brefeldinA (5μg/mL, green). Data are 
mean ± SD, n = 8. (e,f) Effects of different stimuli on proguanylin secretion, measured by immunoassay, from 
human duodenal organoids (e) and human colonic organoids (f) Cultures were incubated with 50 mM NaCl, 
100 mM mannitol, 100 nM bombesin, 1 mM carbachol, 5 mg/mL peptone, forskolin/IBMX (10 μM each), 1 μM 
PMA, 100 μM taurodeoxycholic acid (TDCA) or 100 nM aldosterone for 24 h. Data were normalised to total 
protein content and to the mean basal value. Data are mean ± SD, n = 6–18. (g–j) Secretion and expression of 
proguanylin in TC7 cells in response to different stimuli. TC7 cultures were incubated with stimuli as in (e). 
Supernatant proguanylin levels, measured by immunoassay (g,i) as well as transcript levels (h,j) were measured 
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proguanylin release and transcript levels were also increased by peptones, and a small reduction in secretion was 
found in PMA-treated wells (Fig. 8i,j). At this later timepoint with forskolin/IBMX, the GUCA2A transcript levels 
were not significantly different from controls (Fig. 8j).
As we had inconsistent results in these different culture systems, with only forskolin/IBMX apparently increas-
ing proguanylin release in TC7 cells, we quantified proguanylin in cell supernatants and cell extracts at different 
time points over 24 hours. After 4 h, the amount of proguanylin in the supernatant, measured by immunoassay, 
was similar to that found in cell lysates, and after longer incubations the supernatant concentrations increased 
approximately linearly, whereas the lysate content stayed relatively constant (Fig. 8c,d). These results suggest 
that the cells turn over their entire proguanylin content in approximately 4 hours. In cells treated with forskolin/
IBMX, slightly higher supernatant proguanylin concentrations were detected after 8 and 24 hours, correspond-
ing with a small increase in the lysate content at 8 h. The slightly higher secretory rate in forskolin/IBMX might 
therefore reflect a stimulation by cAMP of proguanylin biosynthesis. When TC7 cells were treated for 4 or 8 hours 
with brefeldin A, an inhibitor of ER/Golgi transport, proguanylin secretion was largely abolished, although lysate 
concentrations remained unchanged (Fig. 8c,d), suggesting that ER/Golgi transport is required for proguanylin 
secretion, and that there is very little storage of proguanylin in post-Golgi compartments.
Discussion
In this study, we applied new tools to investigate the cellular origin and secretion of guanylin peptides, includ-
ing a new immunoassay for human proguanylin, LC-MS/MS analysis of proguanylin-derived peptides, and a 
transgenic mouse model expressing Venus under the control of the proguanylin promoter that enabled the iden-
tification, isolation and transcriptomic analysis of proguanylin-expressing cells. We found that proguanylin is 
constitutively secreted into the gut lumen, predominantly by mature enterocytes in the distal small and the large 
intestine, but in the duodenum only by Goblet and Paneth cells.
Guanylin and uroguanylin have been reported to exhibit differential expression along the GI tract, with 
Guca2b mainly expressed in the proximal small intestine and Guca2a mainly expressed in the distal small intes-
tine and the colon16,36. Using the Guanylin-Venus transgenic mouse, we observed guanylin-dependent fluores-
cence in a variety of intestinal cell types and found that the purified fluorescent cell populations were enriched 
for both Guca2a and Guca2b. The pattern of Venus fluorescence in the duodenum was atypical compared with 
the rest of the GI tract, as it was largely restricted to Paneth and goblet cells. In the remainder of the gut, these cell 
types were also fluorescent, but we additionally observed expression in “mature” enterocytes at the small intestinal 
villus tips and the colonic surface epithelium. These results are in agreement with a recent RNAscope analysis16 
which found a similar distribution of guanylin and uroguanylin along the murine rostro-caudal and crypt-villus 
intestinal axes. Unlike this murine RNA-scope analysis, we did not find tuft cell markers in guanylin-Venus cells, 
but our results are consistent with a recent study that failed to detect GUCA2A in human and rat tuft cells37, and 
another report suggesting that uroguanylin but not guanylin is expressed in this cell type18. In agreement with 
the RNA-scope studies16,37, we found no evidence for guanylin expression in enteroendocrine cells, contrasting 
with reports showing expression in human or rat enteroendocrine cells by immunohistochemistry12,13,28. Whilst 
these previous studies themselves are inconsistent by identifying different enteroendocrine subpopulations (EC-, 
D- and L-cells) to express guanylin, possibly due to antibody cross-reactivity, we cannot exclude possible species 
differences.
LC-MS/MS analysis of human plasma readily detected full length proguanylin, consistent with our meas-
urement of high circulating proguanylin concentrations by immunoassay. Shorter proguanylin fragments were 
not detectable by LC-MS/MS in human plasma. In media from murine Ussing chamber studies, we detected 
full length proguanylin together with lower levels of a variety of cleaved forms. Our finding that full length 
proguanylin (22–116/115) is the major released form is consistent with previous reports in humans and rats38–40. 
Whilst we did not detect the originally described canonical sequence for the 15aa long active guanylin (mouse 
102–116/human 101–115)41, we regularly and consistently detected peptides that were one amino acid shorter 
or longer at the N-terminus, as also reported previously for rats and humans38,40 thus suggesting that the orig-
inally isolated guanylin 15-mer likely represents an artefact of the acetic extraction method as previously pro-
posed42. In murine tissue extracts, LC-MS/MS confirmed the previously-observed proximal to distal gradient of 
proguanylin-peptides, and identified a variety of proguanylin cleavage products, some of which matched those 
found to be secreted in the Ussing chamber studies (mouse 101–116 and 103–116). As we were not able to quan-
tify the relative proportion of cleaved to full-length proguanylin in the tissue extracts, it is not clear how much 
proguanylin processing occurs intracellularly and how much depends on enzymatic cleavage in the gut lumen 
or bloodstream. Although the enzymes responsible for luminal proguanylin processing remain unknown, we 
speculate a role for meprins, which are zinc metalloproteinases found highly expressed in the small intestinal 
epithelial brush border43, with sequence specificity predicted to cleave proguanylin to release the 16 amino acid 
long guanylin peptide, but of course future research will be required to investigate if proguanylin is a substrate for 
these metalloendo-peptidases.
In agreement with previous studies on rat tissues2,44, we found that proguanylin is predominantly secreted 
into the gut lumen rather than at the basolateral side, in sharp contrast to enteroendocrine hormones such as 
after 4 h incubation (g,h) and 24 h incubation. (i,j) Measured proguanylin concentrations were normalised 
to the mean basal value in control wells per experiment. Gene expression was calculated using the 2ΔΔCt 
method, normalising to β-act and the relative expression in control (basal) wells for each experiment. Data are 
mean ± SD, n = 9–17 from 3–6 independent experiments. Responses were analysed by ANOVA followed by a 
Dunnett test. ***P < 0.001, **P < 0.01, *P < 0.05.
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GLP-1. This finding was observed in both mouse and human intestine and is consistent with the localisation 
of guanylin-expression in goblet and Paneth cells, which are specialised to secrete peptides and mucus in the 
luminal direction. Proguanylin was also, however, detectable in the basolateral compartment of Ussing chamber 
experiments, albeit at lower levels than in the luminal chamber, consistent with its detection in human plasma. As 
it seems unlikely that proguanylin arrives in the circulation following its diffusion/leakage out of the gut lumen 
across the epithelial layer, there should be an additional secretory pathway in the basolateral direction from a 
cell type that remains unclear. Our finding that proguanylin was undetectable in the plasma of a patient who 
temporarily lacked an intestine prior to transplantation, argues against the possibility that circulating progua-
nylin derives from a non-intestinal source. The observation that bowel transplant patients had raised fasting 
plasma proguanylin levels is interesting and in line with previous reports of elevated proguanylin expression 
after Roux-en-Y gastric bypass surgery28. The variety of operations performed, ranging from isolated small bowel 
transplants to multivisceral transplants including liver and pancreas, however, prevents currently a more detailed 
analysis of what might upregulate proguanylin secretion into the plasma after surgery.
We were unable to identify clear stimuli of guanylin secretion in vitro, although these studies were limited 
by the cellular models available. TC7 cells did not exhibit strong evidence of regulated proguanylin release, but 
cellular content had a rapid turnover and secretion was blocked by brefeldin A, arguing for a continuous consti-
tutive vesicular secretory pathway. As TC7 cultures would not have contained goblet and Paneth cells, intestinal 
organoids and primary intestinal cultures were used as an alternative in the hope they might have contained a 
mixture of cell types, but these also failed to exhibit robust secretion in response to candidate stimuli. PMA inhib-
ited proguanylin secretion from organoid cultures over a 24 hour incubation, whereas it had no effect on secretion 
from TC7 cells over a similar timeframe and slightly stimulated secretion from primary cultures during a 1 hour 
incubation. The underlying explanation for the different responses of the two models is unclear but might reflect 
the different incubation times and the presence of different cell types in organoids and primary cultures, whereas 
TC7 cells are of an enterocyte lineage. We were also unable to provide convincing evidence in support of previous 
reports that guanylin levels are linked to increased sodium levels20. Our data are best compatible with the idea that 
proguanylin secretion from enterocytes occurs constitutively, with limited storage of acutely recruitable vesicu-
lar pools, as proguanylin accumulated over time in TC7 supernatants, but not in the cells themselves. Previous 
reports of carbachol-triggered proguanylin release from intact tissue pieces mounted in Ussing chambers2 and 
bethanechol-stimulated release from perfused colonic preparations44 might reflect degranulation of goblet cells, 
which are known to respond to cholinergic stimulation45. Moro et al. also showed that bombesin-stimulated 
proguanylin release was inhibited by tetrodotoxin, suggesting the involvement of the enteric nervous system 
(ENS), possibly explaining the lack of a response seen in the here employed culture systems, as these would lack 
the ENS.
Proguanylin concentrations in human plasma averaged ~15 ng/ml, approximately 1000-fold higher than fast-
ing plasma levels of gut hormones such as GLP-1, and were largely unaffected by food or glucose ingestion. Taken 
together with the finding that secretion in vitro was largely unresponsive to a range of candidate stimuli, our data 
do not support the idea that plasma proguanylin acts as a classical hormonal signal related to nutrient intake. 
Indeed, although elevated proguanylin levels were reported previously in bariatric patients, consistent with our 
own findings, administration of proguanylin or guanylin in mouse models did not influence food intake or glu-
cose homeostasis28. As GC-C is predominantly expressed in the GI tract, it remains uncertain whether circulating 
proguanylin has any signalling role.
Proguanylin released into the intestinal lumen is cleaved into smaller peptides, and although we did not detect 
the classical 15 amino acid guanylin peptide, we consistently found slightly longer and shorter peptides that are 
likely to exhibit activity on the GC-C receptor. It has been hypothesised previously that guanylin secreted by 
Paneth cells deep inside the crypts might activate CFTR in neighbouring enterocytes thus sustaining luminal fluid 
flow from the crypt to villus, whilst guanylin secreted by goblet cells could similarly provide water for full mucin 
hydration16. Guanylin released from the villus tips could potentially target nearby or distal enterocytes, providing 
a paracrine/autocrine feedback mechanism to ensure adequate epithelial hydration16. As full length proguanylin 
has limited activity at the GC-C receptor46, enzymatic processing in the brush border is essential for activity.
Future studies will be required to identify specific release pathways involved in secretion from the different 
cell types producing proguanylin, the mechanisms and enzymes regulating active guanylin generation in the gut 
lumen, and the physiological roles (if any) of circulating proguanylin.
Materials and Methods
Unless otherwise stated, all chemicals were supplied by Sigma-Aldrich.
ethical approvals. Ethical approval for collection of human plasma samples was granted by the following 
National Research Ethics Committees: East of England – Cambridgeshire and Hertfordshire (ref: 13/EE/0195), 
East of England – Norfolk (ref: 14/EE/1247); and East of England – Cambridge South (ref: 16/EE/0338). Ethical 
approval for use of human tissue pieces for cell culture, organoid generation and Ussing chamber studies was 
granted by the East of England – Cambridge Central Research Ethics Committee (ref: 09/H0308/24); surgical 
specimens were obtained under this ethical approval from Tissue Bank at Addenbrooke’s Hospital (Cambridge, 
UK). All human studies were conducted in accordance with the ethical standards of the Helsinki Declaration of 
1975. All human participants gave written informed consent, either themselves or through their parent and/or 
legal guardian if they were under the age of 18 years old, and all methods were performed in accordance with the 
relevant guidelines and regulations.
Animal procedures during the generation of antibodies were approved by the Babraham Institute Animal 
Welfare and Ethical Review Body. Animal procedures involving the generation and/or use of Guanylin-Venus 
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mice were approved by the University of Cambridge Animal Welfare and Ethical Review Body. All animal 
experiments were performed in accordance with the relevant guidelines and regulations under the UK Home 
Office project licences 70/8084, 70/7824 and PE5OF6065 and were carried out in accordance with the Animals 
(Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039).
Human blood samples. Healthy volunteers and patients who had previously undergone prophylactic total 
gastrectomy were recruited for oral glucose tolerance tests (50 or 75 g OGTTs) or mixed liquid meal (Ensure plus) 
and blood was collected just before and 60 minutes after ingestion into lithium-heparin coated tubes and centri-
fuged 10 min at 4 °C at 3500 g, plasma was stored at −80 °C until analysis47. Other blood samples were obtained 
from patients having received small bowel transplants and healthy volunteers after an overnight fast and serum 
samples were stored at −80 °C until analysis.
transgenic mice generation. BAC constructs containing the sequence of the yellow fluorescent protein 
Venus driven by the mouse guanylin promoter were made by the RedEt technique48. Briefly the sequence in 
the 3 exons coding for Guca2a (Guanylin) from the start codon to the stop codon in the murine-based BAC 
RP23-104G3 (Source Bioscience) was initially replaced by a counter-selection cassette RpsL-neo (GeneBridges) 
and subsequently by the Venus sequence49 using Red/ET recombination technology (Genebridges). The RpsL/
Neo (FSD001/FSD002) or Venus (FSD003/FSD004) sequences were amplified by PCR with Phusion-polymerase 
adding Guca2a-gene specific 3′ and 5′ sequences (Table 1). Positive recombinants were isolated using appropri-
ate antibiotic selection and characterised by PCR. The identity and correct positioning of the introduced Venus 
sequence was confirmed by direct sequencing using oligonucleotides FSD045-FSD076 (Table 1) and restriction 
analysis using the ZraI enzyme (NEB) for DNA fingerprinting. The BAC was purified using a Maxi-Prep (Qiagen) 
and diluted to 1 ng/μL into injection buffer (10 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 100 mM NaCl, 0.03 mM 
spermine, and 0.07 mM spermidine). The Central Biomedical Services (University of Cambridge) performed the 
pronuclear injection of ova derived from C57Bl6J/CBA F1 crosses, which were implanted into pseudopregnant 
females. Integration of the transgene was screened by PCR on the pups’ ear clips after extracting the DNA by 
proteinase K digestion using the primers GFPF1 and GFPR1 (Table 1). Experiments were performed on tissue 
derived from animals backcrossed into C57Bl6J to varying degree (3–8 generations), with no changes having been 
observed in the expression profile along the intestinal axis during the backcrossing procedure.
immunohistochemistry. Tissues from different regions of mouse gut were fixed in 4% PFA (Alfa Aesar) at 
room temperature overnight, dehydrated in sucrose (6 h 15% followed by 24 h 30%) at 4 °C. Tissue was embedded 
in OCT (VWR) and sectioned (7–10 μm) using a cryostat and mounted on Superfrost Plus glass slides (Thermo 
Fisher Scientific). Tissues sections were blocked in 10% donkey serum and 1% BSA and permeabilized with 
0.05% Tween-20. Slides were stained with primary antibodies diluted in blocking solution over night at room 
temperature (RT) (Table 2). Slides were washed in PBS and 0.05% Tween-20 and then incubated with secondary 
antibodies conjugated to Alexa-Fluor 488, 555 or 633 (Invitrogen) and Hoechst nuclear stain (1:1300). Sections 
were mounted in hydromount (National Diagnostics) and images taken using a TCS SP8 confocal microscope 
using LAS software (Leica).
Primary murine intestinal single-cell digestion for fluorescence-activated cell sorting. Four 
distinct parts of the gastrointestinal tract corresponding to the duodenum (top 3 cm of the small intestine), jeju-
num (3 cm in the middle small intestine) and ileum (bottom 3 cm of the small intestine) as well as the whole colon 
and rectum were treated separately and digested into single cells50. Each intestine part was opened longitudinally, 
rinsed in PBS and the outer muscle layer was removed. Each part was incubated in 10 mL solution containing 
15 mM EDTA (or 30 mM for colon) and 1 mM DTT in Ca2+-free PBS for 7 minutes at RT. Tissue pieces were 
transferred into 15 mL Ca2+-free PBS with 10 μM ROCK inhibitor y27632 (Tocris) and shaken by hand for 30 sec-
onds to collect epithelial fragments, and tissue transferred back to the EDTA solution. Incubation in EDTA and 
shaking was repeated 5 times. Epithelium fragments were kept on ice and after final shaking, centrifuged at 500 g 
at 4 °C and media was removed and replaced with 10 mL Trypsin 0.25% EDTA, 100 mg/mL DNAseI for 5 minutes 
at 37 °C. 15 mL of Hanks’ buffered salt solution (HBSS) supplemented with 10% FBS and 5 μM y27632 was added 
and cells triturated before centrifugation at 500 g at 4 °C for 5 minutes. Cells were resuspended in 10 mL washing 
solution (HBSS with 0.1% BSA and 5 μM y27632) and filtered through 100 µm and 50 µm cell filters. Single cells 
were pelleted again (500 g at 4 °C for 5 minutes), and resuspended in 150 µL of the washing solution containing an 
anti-CD45-PE antibody (1/500) (Thermo Fisher #MA110233) for 1 h on ice. Cells were centrifuged at 500 g at 4 °C 
for 5 minutes, resuspended in 200 µL washing solution containing DAPI and incubated for 5 minutes. Cells were 
washed twice with 1 mL washing solution and finally resuspended in 500 µL washing solution containing 5 µM 
DRAQ5 (Fisher Scientific). Single cell suspensions were sorted within 2 h on a FACSJazz (BD) at the Cambridge 
NIHR BRC Cell Phenotyping Hub. For each tissue, cells with high Venus fluorescence and non-fluorescent cells 
were sorted directly into lysis buffer (RLT plus, Qiagen) whilst dead cells, nucleus-free remnants and immune 
cells were excluded on the basis of DAPI, DRAQ5 and CD45 staining, respectively.
RNA extraction, RNA sequencing and RT-qPCR. Total RNA from FACS-isolated cells was extracted 
using RNAeasy Micro Plus kit (Qiagen) according to the manufacturer’s instructions and concentration and 
quality assessed using a Bioanalyser RNA Pico kit (Agilent). RNA samples with RNA integrity number values 
between 8.6 and 10 were used. Libraries were prepared and amplified using SMARTer Pico V2 Mammalian prep 
kit (Takara) from 10 ng of RNA. Libraries were single-end 50 base pair sequenced at CRUK Cambridge on an 
Illumina HiSeq. 4000 platform. The average total number of reads in each sample was 32.3 million with an aver-
age of 21.4 million mapping uniquely to the mouse genome GRCm38 using STAR51. Read counts per gene were 
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determined using STAR and differential gene expression was determined using DESeq. 252. Raw data and gener-
ated count table are available with the GEO accession number GSE128117.
RNA from homogenised tissues and cell cultures were extracted using TRI Reagent following standard proto-
cols. RNA was treated with DNAse I (Ambion), and reverse transcription was performed using the High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). RNA from sorted cells was reverse-transcribed using 
superscript III (Invitrogen) according to the manufacturer’s protocol. RT-qPCR was performed using the fast 
Taqman universal mastermix and the Taqman probes listed in Table 3 on a QuantStudio 7 (Applied Biosystems). 
Gene expression was measured relative to that of β-actin measured in parallel in the same sample using the ΔCt 
method.
Mass spectrometry. Plasma samples were extracted using ACN precipitation further purified using an HLB 
Prime μElution solid‐phase extraction (SPE) plate (Waters, MA, USA)53, whilst the Ussing chamber samples 
were extracted using SPE only. Peptides extracts were analysed using a Thermo Fisher Ultimate 3000 LC sys-
tem coupled to a Q Exactive Plus Orbitrap mass spectrometer (ThermoScientific, San Jose, USA) as previously 
described54. LC-MS/MS data were analysed using Peaks v8.5 to identify peptides sequences on the Mus muscu-
lus and Homo sapiens Swissprot databases (downloaded on 26/10/2017) and XCalibur 4.1 (ThermoFisher) to 
Primer Purpose Sequence (5′-3′)
FSD001 Replacement GN by rspL/neoR cassette forward GCCCCACTGTTTACCCCAGGCACTAGTACTGGCCTGTTCTCTG CATTGCATACTGCTACCGGCCTGGTGATGATGGCGGGATCGT
FSD002 Replacement GN by rspL/neoR cassette reverse CTTCTAGAAGATAGAGGGGCTTCCACATGGGCTGAGAGAAAGG CAAGCGATGTCACTCTAGAAGAACTCGTCAAGAAGGCGATAG
FSD003 Replacement GN by Venus cassette forward GCCCCACTGTTTACCCCAGGCACTAGTACTGGCCTGTTCTCTG CATTGCATACTGCTACCATGGTGAGCAAGGGCGAGGAGCTGT
FSD004 Replacement GN by Venus cassette reverse CTTCTAGAAGATAGAGGGGCTTCCACATGGGCTGAGAGAAAG GCAAGCGATGTCACTCTACTTGTACAGCTCGTCCATGCCGAGA
FSD045 To sequence GN-Venus + −5000bp f1 CTCCAGGAGGAGGAAAAAGAG
FSD046 To sequence GN-Venus + −5000bp f2 CAGTGAGCTCCAGCTCACTG
FSD047 To sequence GN-Venus + −5000bp f3 CAAACCGTGCCACTTTATTTC
FSD048 To sequence GN-Venus + −5000bp f4 CTGGCTTGCCAGAAGATGATG
FSD049 To sequence GN-Venus + −5000bp f5 CAGCAGCCTCCACACTCGAG
FSD050 To sequence GN-Venus + −5000bp f6 CTTTGCACACATGCCTTTCAG
FSD051 To sequence GN-Venus + −5000bp f7 CTTCTTCATCGAGGGCTTCC
FSD052 To sequence GN-Venus + −5000bp f8 CAGCAGATGAGGCTGACAAG
FSD053 To sequence GN-Venus + −5000bp f9 CTCCTGGGGTCACTAACTTGC
FSD054 To sequence GN-Venus + −5000bp f10 CCTGATCTTCCACATCCTGTG
FSD055 To sequence GN-Venus + −5000bp f11 GGTACACAGCTTCCTCCCAG
FSD056 To sequence GN-Venus + −5000bp f12 CTGAAAGCTGTCTCAGCATGG
FSD057 To sequence GN-Venus + −5000bp f13 GACAACCCAGGAAGCATCAAG
FSD058 To sequence GN-Venus + −5000bp f14 GAACACTTGGTCCCAGTAGGTG
FSD059 To sequence GN-Venus + −5000bp f15 GGCAGAGAGTAGCTGGGTGTAG
FSD060 To sequence GN-Venus + −5000bp f16 GGACGTGTCACTCCCTGATTG
FSD061 To sequence GN-Venus + −5000bp r1 GTGTTGCTTCTTTGATTGGTCTG
FSD062 To sequence GN-Venus + −5000bp r2 CAATCAGGGAGTGACACGTCC
FSD063 To sequence GN-Venus + −5000bp r3 CTACACCCAGCTACTCTCTGCC
FSD064 To sequence GN-Venus + −5000bp r4 CACCTACTGGGACCAAGTGTTC
FSD065 To sequence GN-Venus + −5000bp r5 CTTGATGCTTCCTGGGTTGTC
FSD066 To sequence GN-Venus + −5000bp r6 CCATGCTGAGACAGCTTTCAG
FSD067 To sequence GN-Venus + −5000bp r7 CTGGGAGGAAGCTGTGTACC
FSD068 To sequence GN-Venus + −5000bp r8 CACAGGATGTGGAAGATCAGG
FSD069 To sequence GN-Venus + −5000bp r9 GCAAGTTAGTGACCCCAGGAG
FSD070 To sequence GN-Venus + −5000bp r10 CTTGTCAGCCTCATCTGCTG
FSD071 To sequence GN-Venus + −5000bp r11 GGAAGCCCTCGATGAAGAAG
FSD072 To sequence GN-Venus + −5000bp r12 CTGAAAGGCATGTGTGCAAAG
FSD073 To sequence GN-Venus + −5000bp r13 CTCGAGTGTGGAGGCTGCTG
FSD074 To sequence GN-Venus + −5000bp r14 CATCATCTTCTGGCAAGCCAG
FSD075 To sequence GN-Venus + −5000bp r15 GAAATAAAGTGGCACGGTTTG
FSD076 To sequence GN-Venus + −5000bp r16 CAGTGAGCTGGAGCTCACTG
GFPF1 mouse screening GACGTAAACGGCCACAAGTT
GFPR1 mouse screening GGATCTTGAAGTTCGCCTTG
Table 1. Table of primers.
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quantify peptides measuring signal peak areas for specific sets of m/z and retention time corresponding to the 
identified peptides. Quantification of the guanylin peptides along the mouse intestine was analysed on previously 
published LC-MS/MS data (ProteomeXchange PXD009788, 10.6019/PXD009788)47.
Antibody generation. The production and purification of soluble proguanylin in E. coli was described by 
Lauber and collaborators55. This method was used to produce 25 mg of proguanylin for the hybridoma generation, 
screening and assay development. The purified protein was subjected to endotoxin removal using Polymyxin B 
resin56. To perform the primary screen of the hybridoma clones and IgG characterisation, 2 mg of proguanylin was 
enzymatically biotinylated using the BirA enzyme (Avidity LLC #BirA500) according to manufacturer’s instruc-
tions. Female CD1 mice aged 6–8 weeks were used for hybridoma generation and injected subcutaneously with 
100 µg of recombinant proguanylin followed by 3 boosts of 100 µg each over 21 days. The immunisation, hybri-
doma generation and cDNA preparation and variable chain sequencing and IgG purification were performed as 
previously described57. For the clone selection, a Homogeneous Time Resolved Fluorescence biochemical assay 
was developed to measure the binding of IgGs to the biotinylated targets using Europium cryptate conjugated 
streptavidin (Cisbio #610SAKLB) as the donor and AlexaFluor 647 conjugated goat anti-mouse Fc IgG (Jackson 
#115-605-164) as the acceptor. Test samples were incubated for 15 h at RT with 2.5 nM biotinylated-Proguanylin 
premixed with 1 nM Streptavidin-cryptate, and 7.5 nM AlexaFluor 647 conjugated goat anti-mouse Fc IgG. The 
fluorescence was measured on an EnVision plate reader (Perkin Elmer) using a 320 nm excitation filter and 
665 nm and 590 nm emission filters.
cell culture. TC7 cells (RRID:CVCL_0233, a sub-clone of the caco-2 cell line58) were previously characterized 
as differentiating epithelial cells59 and were cultured in Dulbecco’s modified Eagle’s medium (DMEM, 4.5 g/L glu-
cose) supplemented with 10% Fetal Bovine Serum (FBS), 100 units/mL penicillin, 100 μg/mL streptomycin and 2 
mM L-glutamine at 37 °C, 5% CO2 and passaged every 7 days.
Human organoid lines were generated using a modified protocol60,61. Briefly, fresh surgical specimens of 
fresh human duodenum and colon were minced, and fragmented with 30 mM EDTA for 3 × 10 mins, with tissue 
shaken in PBS after each EDTA treatment. The fraction with intestinal crypts was then further digested using 
TrypLE (Life Technologies) for 5 mins at 37 °C to generate small cell clusters, which were seeded into basement 
membrane extract (BME, R&D technology), with 20 μl domes polymerised in multiwell dishes for 30–60 mins 
at 37 °C. Organoid medium61 was then overlaid and changed 3 times per week. Organoids were passaged every 
10–21 days, with TrypLE digestion for 15 mins at 37 °C followed by mechanical shearing with rigorous pipetting 
for 30 times to breakup organoids into small clusters which were then seeded as before in BME. To generate dif-
ferentiated cell types, organoid domes were washed 3 times in Advanced DMEM/F12 over 1 h. Organoid media 
lacking wnt3A, SB202190, A83-01 and nicotinamide was then added to the wells and changed every day for up 
to 10 days.
Secretion assay. Mouse primary cultures were prepared as described62. Briefly, colons from individual mice 
were harvested and digested with 0.4 mg/mL collagenase XI. Isolated crypts were plated on matrigel overnight 
and the day after, cells were rinsed with secretion buffer ((in mM) 5.6 KCl, 138 NaCl, 4.2 NaHCO3, 1.2 NaH2 PO4, 
2.6 CaCl2, 1.2 MgCl2, and 10 HEPES, pH 7.4 and 0.001% BSA) 3 times over 30 minutes and incubated in secretion 
buffer with indicated drugs for 1 h. Supernatant was then collected and centrifuged 5 min at 2,000 g at 4 C and 
transferred to a fresh Protein Lobind tube before purification through an SPE plate and analysis by LC-MS/MS 
as described.
Differentiated TC7 cells (grown at confluency for 9 days) or 8–9 day old differentiated human organoids were 
used for secretion experiments. The wells were washed 3 times in culture medium. Test agents were dissolved in 
the same medium and 250 μL applied for TC7 secretions, or 150 μL applied for organoid secretions. TC7 cells 
or organoids were incubated at 37 °C for 4 h, 8 h, or 24 h. Medium was centrifuged for 10 mins at 350 g at 4 °C, 
with supernatant used for downstream analysis. For experiments that required cell lysates to measure total pro-
forms or total protein levels, the cells were lysed in 150 μL of lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% 
IGEPAL-CA630, 0.5% deoxycholic acid, and one tablet per 50 mL of complete EDTA-free protease inhibitor 
cocktail (Roche)) on ice for 30 mins, centrifuged at 10,000 g for 10 mins at 4 °C and the supernatants analysed.
Use Antibody target Company and catalog number RRID Dilution
hybridoma FITC labelled monoclonal antibody anti-mouse IgG Jackson ImmunoResearch (115-095-164) AB_2338600 10 μg/mL
HTRF assay AlexaFluor 647 labelled goat anti mouse Fc IgG Jackson ImmunoResearch (115-605-164) AB_2338913 7.5 nM
Cell sorting anti-CD45-PE Thermo Fisher (MA110233) AB_11153376 1/500
IC Donkey anti-mouse 647 Life technologies (A31571) AB_162542 1/300
IC Donkey anti-goat 488 Life technologies (A11055) AB_2534102 1/300
IC Donkey anti-rabbit 555 Life technologies (A31572) AB_162543 1/300
IC Goat anti-GFP Abcam (Ab5450) AB_304897 1/1000
IC Rabbit anti-Lysozyme Dako (A0099) AB_2341230 1/200
IC Rabbit anti-Muc2 Santa Cruz (sc15334) AB_2146667 1/200
IC Mouse anti-E-cadherin BD (610181) AB_397580 1/200
Table 2. Table of antibodies and antisera used.
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Ussing chamber secretion experiments were performed with minor modifications as described previously63.
Human and mouse intestinal tissue was transported to the laboratory in ice-cold L15 medium. Serosa and most 
of the muscular layers were stripped away with fine forceps and the remaining tissue was mounted in an Ussing 
chamber (EM-LVSYS-4 system with P2400 chambers and P2405 sliders; Physiologic Instruments). The active 
epithelial surface area of each segment was 0.4 cm2. Both parts of the Ussing chambers were filled with Ringer 
solution containing 120 mM NaCl, 3 mM KCl, 0.5 mM MgCl2, 1.25 mM CaCl2, and 23 mM NaHCO3, with 
10 mmol/L glucose, maintained at 37 °C, and continuously bubbled with 5% CO2/95% O2 (vol/vol). The transepi-
thelial potential difference was monitored under open circuit conditions, using a DVC 1000 amplifier (WPI) and 
recorded through Ag-AgCl electrodes and 150 mM NaCl agarose bridges. After 20–30 minutes, solutions from 
both sides were exchanged with 1.2 mL of fresh Ringer solution containing 10 mM glucose, 0.1% fatty acid–free 
BSA, 10 μM amastatin, 500 kIU/mL aprotinin and Infacol (Forest Laboratories, 1:105 dilution, to prevent exten-
sive foam formation). Solutions for LC-MS/MS only contained the additives 10 mM glucose and 0.001% BSA. 
Samples (120 μL) were taken from both compartments typically at 10, 40 and 85 minutes after solution exchange. 
IBMX (100 μM) and forskolin (10 μM) were added bilaterally immediately after the second sample was taken at 
40 min. Reported secretion was normalized for 1 cm2 of the tissue and a 60-minute secretion period. GLP-1 and 
Proguanylin were measured by MSD immunoassay or LC-MS/MS as indicated.
MSD assay. Anti-ProGuanylin antibody AB1000025 was coated using 5 µL of 50 ng/µL on an assay plate 
(MSD #MA6000) incubated at RT overnight. Plates were blocked using 1% BSA in PBS for 2 h at RT. After wash-
ing 3 times with washing buffer (PBS-Tween (0.05%)), 25 µL of samples were added to each well and incubated for 
2 h at RT. Following incubation, plates were washed 3 times with washing buffer and 25 µL of a second Sulfo-Tag 
labelled anti-ProGuanylin antibody AB1000028 prepared at 1 µg/mL in Diluent 41 (MSD) was added per well for 
1 h at RT. Once washed with washing buffer, 150 µL of Read buffer 2X was added to each well before reading the 
plate immediately using a MSD Workbench. A standard curve was constructed by fitting a sigmoidal function 
to the absorbance obtained from the known proguanylin concentrations and the concentration of experimental 
samples was assessed by interpolating them to the standard curve using the MSD discovery software. Samples in 
lysis buffer were diluted 1/20, dilution at which the lysis solution had no effect on measurements. GLP-1 concen-
trations in Ussing chamber experiments were measured at the Core Biochemical Assay Laboratory (Cambridge) 
using the total GLP-1 assay kit from MSD (K150JVC, RRID AB_2801383).
Data availability
The datasets generated during and/or analyzed during the current study, the animal model (Guanylin-Venus) and 
the immuno-assay developed during this study are not publicly available but are available from the corresponding 
author on reasonable request. The RNAseq data has been deposited as outlined in material and methods.
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Gene Species
TaqMan™Gene Expression Assay Id
Guanylin (Guca2a) mouse Mm00433863_m1
Uroguanylin (Guca2b) mouse Mm01192051_m1
Beta actin (Actb) mouse Mm02619580_g1
Mucin 2 (Muc2) mouse Mm01276696_m1
Lysozyme (Lyz1) mouse Mm00657323_m1
SAM Pointed Domain Containing ETS Transcription Factor (Spdef gene) mouse Mm00600221_m1
SRY-Box 9 (Sox9) mouse Mm00448840_m1
Villin 1 (Vil1) mouse Mm00494146_m1
Glucagon (Gcg) mouse Mm01269055_m1
Gastric Inhibitory Polypeptide (Gip) mouse Mm00433601_m1
Peptide YY (Pyy) mouse Mm00520716_g1
Cholecystokinin (Cck) mouse Mm00446170_m1
Somatostatin (Sst) mouse Mm00436671_m1
Doublecortin Like Kinase 1 (Dclk1) mouse Mm00444950_m1
Transient Receptor Potential Cation Channel Subfamily M Member 5 (Trpm5) mouse Mm01129032_m1
Chemokine (C-C motif) ligand 9 (Ccl9) mouse Mm00441260_m1
Macrophage Myristoylated Alanine-Rich C Kinase Substrate (Marcksl1) mouse Mm00456784_m11
Leucine Rich Repeat Containing G Protein-Coupled Receptor 5 (Lgr5) mouse Mm00438890_m1
Guanylin (GUCA2A) Human Hs00157859_m1
Uroguanylin (GUCA2B) Human Hs00951189_m1
Beta actin (ACTB) Human Hs01060665_g1
Venus (Yfp) Other Mr03987581_mr
Table 3. Table of Taqman assays probes.
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